NASDAQ:TXG 10x Genomics (TXG) Stock Price, News & Analysis $85.71 +1.60 (+1.90%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$85.50 -0.21 (-0.25%) As of 09/25/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About 10x Genomics Stock (NASDAQ:TXG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get 10x Genomics alerts:Sign Up Key Stats Today's Range$80.72▼$86.1650-Day Range$43.22▼$85.7152-Week Range$11.16▼$86.16Volume3.39 million shsAverage Volume2.65 million shsMarket Capitalization$11.17 billionP/E RatioN/ADividend YieldN/APrice Target$44.00Consensus RatingHold Company Overview 10x Genomics, Inc. develops life science technology for analyzing biological systems at the single-cell and spatial levels. Its platforms are designed to help researchers study gene expression, genetic variation, cell populations and tissue organization with greater detail than conventional laboratory methods. The company’s product portfolio includes the Chromium platform for single-cell analysis, Visium solutions for spatial transcriptomics and tissue profiling, and Xenium in situ platforms for high-resolution analysis of RNA and other biological features within tissue samples. These products generally combine specialized instruments, consumables, reagents and software for use in applications such as oncology, immunology, neuroscience, developmental biology and drug discovery. Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves academic, government, pharmaceutical and biotechnology research organizations worldwide. The company was co-founded by Serge Saxonov, who serves as its chief executive officer, and its technologies are used by researchers seeking to understand complex biological processes and develop new approaches to disease research and precision medicine.AI Generated. May Contain Errors. Read More 10x Genomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreTXG MarketRank™: 10x Genomics scored higher than 27% of companies evaluated by MarketBeat, and ranked 781st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus Rating10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.24, and is based on no strong buy ratings, 5 buy ratings, 11 hold ratings, and 1 sell rating.Downside Risk10x Genomics has a consensus price target of $44.00, representing about 48.7% downside from its current price of $85.71.Amount of Analyst Coverage10x Genomics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 10x Genomics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($0.75) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -145.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -145.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 13.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about 10x Genomics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.05% of the float of 10x Genomics has been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 7.09.Change versus previous monthShort interest in 10x Genomics has recently increased by 3.28%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.53 News Sentiment10x Genomics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for 10x Genomics this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat Follows9 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,810,070.00 in company stock.Percentage Held by Insiders8.84% of the stock of 10x Genomics is held by insiders.Percentage Held by Institutions84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 10x Genomics' insider trading history. Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TXG Stock News HeadlinesInsider Selling: 10x Genomics (NASDAQ:TXG) Director Sells $464,650.37 in StockSeptember 27 at 4:54 AM | americanbankingnews.comInsider Selling: 10x Genomics (NASDAQ:TXG) CEO Sells $2,030,500.00 in StockSeptember 27 at 4:09 AM | americanbankingnews.comYou Won’t Get a Warning Before This Correction HitsGold just broke another record - a classic flight-to-safety signal that the smartest money on Wall Street is already acting on. With the NASDAQ pricing in optimism over fundamentals and global tensions continuing to rise, a market correction could arrive without warning. Our research team just released a free crash-protection guide identifying which stocks and sectors can hold strong even when the broader market crumbles.September 27 at 1:00 AM | StockEarnings (Ad)10x Genomics Insider Sold Shares Worth $464,668, According to a Recent SEC FilingSeptember 25 at 11:22 PM | finance.yahoo.com10x Genomics (NASDAQ:TXG) Stock: Insider Shehnaaz Suliman Sells 5,723 SharesSeptember 25 at 5:37 AM | insidertrades.comAdam Taich Sells 46,388 Shares of 10x Genomics (NASDAQ:TXG) StockSeptember 12, 2026 | insidertrades.com10x Genomics (NASDAQ:TXG) CEO Serge Saxonov Sells 10,486 SharesAugust 29, 2026 | insidertrades.com10x Genomics (NASDAQ:TXG) Director Sells 2,207 Shares of StockAugust 27, 2026 | insidertrades.comSee More Headlines TXG Stock Analysis - Frequently Asked Questions How have TXG shares performed this year? 10x Genomics' stock was trading at $16.31 on January 1st, 2026. Since then, TXG shares have increased by 425.5% and is now trading at $85.71. How were 10x Genomics' earnings last quarter? 10x Genomics (NASDAQ:TXG) announced its earnings results on Thursday, August, 6th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.10. 10x Genomics's quarterly revenue was down 12.7% on a year-over-year basis. Read the conference call transcript. When did 10x Genomics IPO? 10x Genomics (TXG) raised $370 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 10,000,000 shares at $36.00-$38.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager. Who are 10x Genomics' major shareholders? 10x Genomics' top institutional investors include Corient Private Wealth LP (0.13%), California State Teachers Retirement System (0.09%), Public Employees Retirement System of Ohio (0.05%) and Mirador Capital Partners LP (0.05%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Adam Taich, Justin J Mcanear, James Wilbur, Alan Mateo and Shehnaaz Suliman. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 10x Genomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/06/2026Today9/27/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TXG's financial health is in the Green zone, according to TradeSmith. TXG has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:TXG CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,178Year Founded2012Price Target and Rating Average Price Target for 10x Genomics$44.00 High Price Target$70.00 Low Price Target$17.00 Potential Upside/Downside-48.7%Consensus RatingHold Rating Score (0-4)2.24 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.54 million Net Margins-12.18% Pretax Margin-12.14% Return on Equity-9.33% Return on Assets-7.30% Debt Debt-to-Equity RatioN/A Current Ratio5.69 Quick Ratio5.25 Sales & Book Value Annual Sales$616.91 million Price / Sales18.10 Cash FlowN/A Price / Cash FlowN/A Book Value$6.24 per share Price / Book13.74Miscellaneous Outstanding Shares130,291,000Free Float118,773,000Market Cap$11.17 billion OptionableOptionable Beta2.08 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:TXG) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
